1956 - Prevalence and severity of fatigue in castration resistant prostate cancer in Spain: VITAL study

Background

Fatigue is the most common and distressing symptom of which castration resistant prostate cancer (CRPC) patients complain. The little evidence of fatigue prevalence, intensity and interference with daily activities in advanced prostate cancer that exists is mainly restricted to post-docetaxel setting with Abiraterone Acetate (AA). The VITAL study examines the prevalence and intensity of cancer-related fatigue (CRF) in CRPC.

Methods

cross-sectional study of CRPC patients including chemo-naïve metastatic (mCRPC) or high risk M0CRPC (PSADT ≤ 10mo) in routine clinical practice. Fatigue and Quality of Life (QoL) data were collected using validated patient self-reported questionnaires(BFI-SF and FACT-G/P). Fatigue correlation with both patient's and physiciańs perception was assessed.

Results

235 patients were recruited (Jan-Sept 2015). Median age: 75.1 (46.2-92.4), median PSA: 17.8 ng/ml (0-2000), metastatic disease: 68.5%, ECOG 0-1: 90.6%. There was a high prevalence of fatigue (M1:73.9%; M0: 74.3%), with 38.3% of the patients having moderate or severe fatigue. High concordance existed between fatigue physiciańs and patient's perception (Kappa index: 0.818). Cardiovascular and respiratory disorders were associated with an increase of fatigue in the multivariate analysis (OR: 4.7 and 3.6 respectively, p 

Conclusions

Our data show a high prevalence and intensity of fatigue and impact in QoL in chemo-naïve CRPC patients. The study highlights the relevance of fatigue awareness and its management in CRPC patients. Table.